@article{Li2023, 
author = {Ping Li and Yang Liu and Yun Liang and Jian Bo and Sujun Gao and Yongxian Hu and Yu Hu and He Huang and Xiaojun Huang and Hongmei Jing and Xiaoyan Ke and Jianyong Li and Yuhua Li and Qifa Liu and Peihua Lu and Heng Mei and Ting Niu and Yongping Song and Yuqin Song and Liping Su and Sanfang Tu and Jianxiang Wang and Depei Wu and Zhao Wang and Kailin Xu and Zhitao Ying and Qingming Yang and Yajing Zhang and Fengxia Shi and Bin Zhang and Huilai Zhang and Xi Zhang and Mingfeng Zhao and Weili Zhao and Xiangyu Zhao and Liang Huang and Jun Zhu and Wenbin Qian and Weidong Han and Aibin Liang},
title = {2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma},
year = {2023},
journal = {Cancer Biology & Medicine},
volume = {20},
number = {2},
pages = {129-146},
keywords = {CAR T-cell therapy, B-cell non-Hodgkin lymphoma, toxicity, cytokine-release syndrome, clinical management},
url = {https://www.sciopen.com/article/10.20892/j.issn.2095-3941.2022.0585},
doi = {10.20892/j.issn.2095-3941.2022.0585},
abstract = {Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.}
}